{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T20:03:41Z","timestamp":1764965021655,"version":"3.46.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"DOI":"10.7759\/cureus.98534","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T19:59:47Z","timestamp":1764964787000},"source":"Crossref","is-referenced-by-count":0,"title":["Burden of Secondary Hyperparathyroidism Among Patients on Hemodialysis: A Cross-Sectional Study"],"prefix":"10.7759","author":[{"given":"Muhammad","family":"Ikram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayat","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Ayaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arbab","family":"Muhammad Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khushhal Khan","family":"Nungyaal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shad","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waqas","family":"Ur Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"Cunningham J","year":"2011","unstructured":"Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011, 6:913-21. 10.2215\/CJN.06040710","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe S","year":"2006","unstructured":"Moe S, Dr\u00fceke T, Cunningham J, et al.. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006, 69:1945-53. 10.1038\/sj.ki.5000414","journal-title":"Kidney Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4236\/ojneph.2020.102014","article-title":"Parathyroidectomy in chronic haemodialysis in the Nephrology and Haemodialysis Department at the University Hospital Center of Point G in Bamako, Mali","volume":"10","author":"Fongoro S","year":"2020","unstructured":"Fongoro S, Yattara H, Sy S, et al.. Parathyroidectomy in chronic haemodialysis in the Nephrology and Haemodialysis Department at the University Hospital Center of Point G in Bamako, Mali. Open J Nephrol. 2020, 10:135-43. 10.4236\/ojneph.2020.102014","journal-title":"Open J Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5500\/wjt.v5.i4.222","article-title":"Vascular calcification, bone and mineral metabolism after kidney transplantation","volume":"5","author":"D'Marco L","year":"2015","unstructured":"D'Marco L, Bellasi A, Mazzaferro S, Raggi P. Vascular calcification, bone and mineral metabolism after kidney transplantation. World J Transplant. 2015, 5:222-30. 10.5500\/wjt.v5.i4.222","journal-title":"World J Transplant"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2015.12.004","article-title":"Changing bone patterns with progression of chronic kidney disease","volume":"89","author":"Dr\u00fceke TB","year":"2016","unstructured":"Dr\u00fceke TB, Massy ZA. Changing bone patterns with progression of chronic kidney disease. Kidney Int. 2016, 89:289-302. 10.1016\/j.kint.2015.12.004","journal-title":"Kidney Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO Chronic Kidney\u00a0Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters","volume":"92","author":"Ketteler M","year":"2017","unstructured":"Ketteler M, Block GA, Evenepoel P, et al.. Executive summary of the 2017 KDIGO Chronic Kidney\u00a0Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int. 2017, 92:26-36. 10.1016\/j.kint.2017.04.006","journal-title":"Kidney Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02640310","article-title":"Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the \"trade-off\" hypothesis","volume":"5","author":"Guti\u00e9rrez OM","year":"2010","unstructured":"Guti\u00e9rrez OM. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the \"trade-off\" hypothesis. Clin J Am Soc Nephrol. 2010, 5:1710-6. 10.2215\/CJN.02640310","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova T","year":"2011","unstructured":"Isakova T, Wahl P, Vargas GS, et al.. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011, 79:1370-8. 10.1038\/ki.2011.47","journal-title":"Kidney Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.12941213","article-title":"Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study","volume":"10","author":"Tentori F","year":"2015","unstructured":"Tentori F, Wang M, Bieber BA, et al.. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2015, 10:98-109. 10.2215\/CJN.12941213","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/nu15071576","article-title":"Vitamin D and chronic kidney disease association with mineral and bone disorder: an appraisal of tangled guidelines","volume":"15","author":"Bover J","year":"2023","unstructured":"Bover J, Mass\u00f3 E, Gifre L, et al.. Vitamin D and chronic kidney disease association with mineral and bone disorder: an appraisal of tangled guidelines. Nutrients. 2023, 15:10.3390\/nu15071576","journal-title":"Nutrients"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000228076","article-title":"Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients","volume":"113","author":"Schumock GT","year":"2009","unstructured":"Schumock GT, Andress DL, Marx SE, Sterz R, Joyce AT, Kalantar-Zadeh K. Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients. Nephron Clin Pract. 2009, 113:c54-61. 10.1159\/000228076","journal-title":"Nephron Clin Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.10390917","article-title":"Parathyroidectomy in the management of secondary hyperparathyroidism","volume":"13","author":"Lau WL","year":"2018","unstructured":"Lau WL, Obi Y, Kalantar-Zadeh K. Parathyroidectomy in the management of secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2018, 13:952-61. 10.2215\/CJN.10390917","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3894","article-title":"Kidney disease progression does not decrease intestinal phosphorus absorption in a rat model of chronic kidney disease-mineral bone disorder","volume":"35","author":"Vorland CJ","year":"2020","unstructured":"Vorland CJ, Biruete A, Lachcik PJ, Srinivasan S, Chen NX, Moe SM, Hill Gallant KM. Kidney disease progression does not decrease intestinal phosphorus absorption in a rat model of chronic kidney disease-mineral bone disorder. J Bone Miner Res. 2020, 35:333-42. 10.1002\/jbmr.3894","journal-title":"J Bone Miner Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.18203\/2349-3933.ijam20190558","article-title":"A study of secondary hyperparathyroidism in patients with chronic kidney disease in a tertiary care hospital","volume":"2019","author":"Vishnu SH","unstructured":"Vishnu SH, Mahendra KK, Jagadeesan M, et al.. A study of secondary hyperparathyroidism in patients with chronic kidney disease in a tertiary care hospital. Int J Adv Med. 2019:271-5. 10.18203\/2349-3933.ijam20190558","journal-title":"Int J Adv Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone\u00a0disorder (CKD-MBD)","volume":"7","year":"2017","unstructured":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone\u00a0disorder (CKD-MBD). Kidney Int Suppl (2011). 2017, 7.1-59. 10.1016\/j.kisu.2017.04.001","journal-title":"Kidney Int Suppl (2011)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/0300060518786913","article-title":"Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: a short-term clinical study","volume":"46","author":"Mima A","year":"2018","unstructured":"Mima A, Tansho K, Nagahara D, Watase K. Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: a short-term clinical study. J Int Med Res. 2018, 46:4578-85. 10.1177\/0300060518786913","journal-title":"J Int Med Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-017-0364-1","article-title":"Renal osteodystrophy or kidney-induced osteoporosis?","volume":"15","author":"Moe SM","year":"2017","unstructured":"Moe SM. Renal osteodystrophy or kidney-induced osteoporosis?. Curr Osteoporos Rep. 2017, 15:194-7. 10.1007\/s11914-017-0364-1","journal-title":"Curr Osteoporos Rep"},{"key":"ref18","article-title":"Evaluation of secondary hyperparathyroidism in patients undergoing hemodialysis","volume":"19","author":"Rahimian M","year":"2008","unstructured":"Rahimian M, Sami R, Behzad F. Evaluation of secondary hyperparathyroidism in patients undergoing hemodialysis. Saudi J Kidney Dis Transpl. 2008, 19:116-9.","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"ref19","article-title":"Prevalence of secondary hyperparathyroidism in hemodialysis patients","volume":"38","author":"Amjad A","year":"2024","unstructured":"Amjad A, Akram M, Umar RM, Anjum AF, Izhar S. Prevalence of secondary hyperparathyroidism in hemodialysis patients. Proc SZMC. 2024, 38:42-4.","journal-title":"Proc SZMC"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1590\/2175-8239-JBN-2023-0119en","article-title":"Renal osteodystrophy and clinical outcomes: a prospective cohort study","volume":"46","author":"Carbonara CE","year":"2024","unstructured":"Carbonara CE, Barreto J, Roza NA, et al.. Renal osteodystrophy and clinical outcomes: a prospective cohort study. J Bras Nefrol. 2024, 46:e20230119. 10.1590\/2175-8239-JBN-2023-0119en","journal-title":"J Bras Nefrol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199140","article-title":"Severe secondary hyperparathyroidism in patients on haemodialysis is associated with a high initial serum parathyroid hormone and beta-CrossLaps level: results from an incident cohort","volume":"13","author":"Jean G","year":"2018","unstructured":"Jean G, Lafage-Proust MH, Souberbielle JC, et al.. Severe secondary hyperparathyroidism in patients on haemodialysis is associated with a high initial serum parathyroid hormone and beta-CrossLaps level: results from an incident cohort. PLoS One. 2018, 13:e0199140. 10.1371\/journal.pone.0199140","journal-title":"PLoS One"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs404","article-title":"Control of mineral metabolism and bone disease in haemodialysis patients: which optimal targets?","volume":"28","author":"Fouque D","year":"2013","unstructured":"Fouque D, Roth H, Pelletier S, et al.. Control of mineral metabolism and bone disease in haemodialysis patients: which optimal targets?. Nephrol Dial Transplant. 2013, 28:360-7. 10.1093\/ndt\/gfs404","journal-title":"Nephrol Dial Transplant"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/418339-burden-of-secondary-hyperparathyroidism-among-patients-on-hemodialysis-a-cross-sectional-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T19:59:48Z","timestamp":1764964788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/418339-burden-of-secondary-hyperparathyroidism-among-patients-on-hemodialysis-a-cross-sectional-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.98534","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,5]]}}}